IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Cwm LLC

Cwm LLC lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,490 shares of the company’s stock after buying an additional 266 shares during the period. Cwm LLC’s holdings in IDEXX Laboratories were worth $1,937,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Blair William & Co. IL increased its holdings in IDEXX Laboratories by 0.7% in the third quarter. Blair William & Co. IL now owns 1,199,945 shares of the company’s stock valued at $524,700,000 after buying an additional 7,812 shares in the last quarter. Brown Advisory Inc. increased its holdings in IDEXX Laboratories by 2.2% in the third quarter. Brown Advisory Inc. now owns 1,161,124 shares of the company’s stock valued at $507,725,000 after buying an additional 24,741 shares in the last quarter. Morgan Stanley increased its holdings in IDEXX Laboratories by 4.7% in the third quarter. Morgan Stanley now owns 1,064,514 shares of the company’s stock valued at $465,482,000 after buying an additional 48,095 shares in the last quarter. Northern Trust Corp increased its holdings in IDEXX Laboratories by 7.7% in the third quarter. Northern Trust Corp now owns 919,191 shares of the company’s stock valued at $401,935,000 after buying an additional 65,891 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in IDEXX Laboratories by 1.4% in the third quarter. Principal Financial Group Inc. now owns 815,863 shares of the company’s stock valued at $356,753,000 after buying an additional 11,315 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling

In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total value of $6,871,320.00. Following the completion of the sale, the chief executive officer now owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Brian P. Mckeon sold 23,326 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the sale, the chief financial officer now owns 29,718 shares of the company’s stock, valued at approximately $16,939,557.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Insiders have sold 43,524 shares of company stock valued at $24,871,960 in the last quarter. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $489.24 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The company has a market capitalization of $40.63 billion, a price-to-earnings ratio of 48.58, a price-to-earnings-growth ratio of 3.81 and a beta of 1.26. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17. The firm’s fifty day moving average price is $532.15 and its 200 day moving average price is $510.35.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. During the same quarter in the previous year, the firm posted $2.05 EPS. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of analyst reports. Barclays raised their target price on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. JPMorgan Chase & Co. lifted their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Piper Sandler lowered shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target on the stock. in a report on Tuesday, January 30th. Finally, The Goldman Sachs Group lifted their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $591.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.